Generic placeholder image

Letters in Drug Design & Discovery

Editor-in-Chief

ISSN (Print): 1570-1808
ISSN (Online): 1875-628X

Research Article

Antimicrobial Activities of Substituted 4-N-alkylated-2-trifluoromethylquinoline Analogs Against Nontuberculous Mycobacteria

Author(s): Emerson Teixeira da Silva, Gabriel Fernandes de Andrade, Maria Cristina Silva Lourenço and Marcus Vinícius Nora de Souza*

Volume 20, Issue 11, 2023

Published on: 27 August, 2022

Page: [1861 - 1866] Pages: 6

DOI: 10.2174/1570180819666220704113825

Price: $65

conference banner
Abstract

Background: Many contagious diseases have been caused by a variety of nontuberculous mycobacteria, opportunistic pathogens that can cause disseminated or localized diseases, particularly pulmonary, skin, and soft tissue infections.

Objective: In this study fifty-five substituted 4-N-alkylated-2-trifluoromethylquinolines were evaluated against five species of nontuberculous mycobacteria: Mycobacterium fortuitum, Mycobacterium chelonae, Mycobacterium abscessus, Mycobacterium kansasii, and Mycobacterium avium.

Methods: The antimycobacterial activities of all tested compounds were assessed using the microplate procedure with broth microdilution assay. The most actives were selected for their potential cytotoxic activity against Vero cells.

Results: Most of the compounds displayed some activity against M. kansaii, of which 12, 15, 34, 37 and 48 were the most active at 3.12 μg/mL. The derivative 8 was the most active against M. fortuitum at 6.25 μg/mL and the most active against M. chelonae at 3.12 μg/mL. The derivative 2 was the most active against M. avium at 12.5 μg/mL, and 9 the most active against M. abscessus at 12.5 μg/mL. All the most active compounds showed MIC values similar to the references drugs used against these species.

Conclusion: 47 compounds displayed some activity against some of the species analyzed, highlighting derivatives 12, 15, 34, 37, and 48, which presented the lower MIC values. Compounds 34 and 37 displayed the highest activity and did not show cytotoxicity against Vero cells. These findings have opened new perspectives for the research of new drugs against these mycobacterial species based on the quinoline nucleus.

Keywords: Quinoline, analogs, drugs, nontuberculous Mycobacteria, antimicrobial activities, tuberculosis.

Graphical Abstract
[1]
Pereira, A.C.; Ramos, B.; Reis, A.C.; Cunha, M.V. Non-tuberculous mycobacteria: Molecular and physiological bases of virulence and adaptation to ecological niches. Microorganisms, 2020, 8(9), 1380-1387.
[http://dx.doi.org/10.3390/microorganisms8091380] [PMID: 32916931]
[2]
Sarro, Y.S.; Butzler, M.A.; Sanogo, F.; Kodio, O.; Tolofoudie, M.; Goumane, M.S.; Baya, B.; Diabate, S.; Diallo, I.B.; Daniogo, D.; Dembele, B.P.P.; Camara, I.; Kumar, A.; Dembele, E.; Kone, B.; Achenbach, C.J.; Theron, G.; Ouattara, K.; Toloba, Y.; Diarra, B.; Doumbia, S.; Taiwo, B.; Holl, J.L.; Murphy, R.L.; Diallo, S.; McFall, S.M.; Maiga, M. Development and clinical evaluation of a new multiplex PCR assay for a simultaneous diagnosis of tuberculous and nontuberculous mycobacteria. EBioMedicine, 2021, 70, 103527.
[http://dx.doi.org/10.1016/j.ebiom.2021.103527] [PMID: 34391092]
[3]
Kothavade, R.J.; Dhurat, R.S.; Mishra, S.N.; Kothavade, U.R. Clinical and laboratory aspects of the diagnosis and management of cutaneous and subcutaneous infections caused by rapidly growing mycobacteria. Eur. J. Clin. Microbiol. Infect. Dis., 2013, 32(2), 161-188.
[http://dx.doi.org/10.1007/s10096-012-1766-8] [PMID: 23139042]
[4]
Li, G.; Lian, L.; Wan, L.; Zhang, J.; Zhao, X.; Jiang, Y.; Zhao, L.; Liu, H.; Wan, K. Antimicrobial susceptibility of standard strains of nontuberculous mycobacteria by microplate alamar blue assay. PLoS One, 2013, 8(12), e84065.
[http://dx.doi.org/10.1371/journal.pone.0084065] [PMID: 24386332]
[5]
van Ingen, J. Diagnosis of nontuberculous mycobacterial infections. Semin. Respir. Crit. Care Med., 2013, 34(1), 103-109.
[http://dx.doi.org/10.1055/s-0033-1333569] [PMID: 23460010]
[6]
Muñoz-Egea, M-C.; Carrasco-Antón, N.; Esteban, J. State-of-the-art treatment strategies for nontuberculous mycobacteria infections. Expert Opin. Pharmacother., 2020, 21(8), 969-981.
[http://dx.doi.org/10.1080/14656566.2020.1740205]
[7]
Ratnatunga, C.N.; Lutzky, V.P.; Kupz, A.; Doolan, D.L.; Reid, D.W.; Field, M.; Bell, S.C.; Thomson, R.M.; Miles, J.J. The rise of non-tuberculosis mycobacterial lung disease. Front. Immunol., 2020, 11, 303.
[http://dx.doi.org/10.3389/fimmu.2020.00303] [PMID: 32194556]
[8]
Villamizar-Mogotocoro, A.F.; Vargas-Méndez, L.Y.; Kouznetsov, V.V. Pyridine and quinoline molecules as crucial protagonists in the never-stopping discovery of new agents against tuberculosis. Eur. J. Pharm. Sci., 2020, 151, 105374.
[http://dx.doi.org/10.1016/j.ejps.2020.105374] [PMID: 32450221]
[9]
Keri, R.S.; Patil, S.A. Quinoline: A promising antitubercular target. Biomed. Pharmacother., 2014, 68(8), 1161-1175.
[http://dx.doi.org/10.1016/j.biopha.2014.10.007] [PMID: 25458785]
[10]
da Silva Araújo, A.; Moraes, A.M.; Lourenço, M.C.S.; Pessoa, C.O.; da Silva, E.T.; de Souza, M.V.N. Synthesis and antibacterial activity of mefloquine-based analogs against sensitive and resistant mycobacterium tuberculosis strains. Curr. Top. Med. Chem., 2019, 19(9), 683-689.
[http://dx.doi.org/10.2174/1568026619666190304124952]
[11]
da Silva, E.T.; de Andrade, G.F.; Araújo, A.S.; Lourenço, M.C.S.; de Souza, M.V.N. Antibacterial activity of new substituted 4-N-alkylated-2-trifluoromethyl-quinoline analogues against sensitive and resistant Mycobacterium tuberculosis strains. Eur. J. Pharm. Sci., 2021, 157, 105596.
[http://dx.doi.org/10.1016/j.ejps.2020.105596] [PMID: 33069867]
[12]
Performance Standards for Susceptibility Testing of Mycobacteria. Nocardia spp., and Other Aerobic ActinomycetesCLSI supplement M62, 1st; Clinical and Laboratory Standards Institute: Wayne, PA, 2018.
[13]
Mosmann, T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J. Immunol. Methods, 1983, 65(1-2), 55-63.
[http://dx.doi.org/10.1016/0022-1759(83)90303-4] [PMID: 6606682]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy